In Brief: Biovail/Hoechst/Marion Merrell Dow
Biovail/Hoechst/Marion Merrell Dow: Bioavail re-acquires license to its once-daily controlled-release diltiazem from Hoechst-Roussel, which licensed the product in 1993, Biovail says April 3. Hoechst is purchasing a controlling interest in Marion Merrell Dow, which filed a patent infringement suit regarding the diltiazem formulation in November 1993. MMD manufactures its own once-daily diltiazem, Cardizem CD. Biovail and Hoechst filed an antitrust suit against MMD Oct. 19, 1994. Within 30 days of the closing of the MMD deal, Hoechst will "withdraw or otherwise dismiss the patent-related complaint" filed by MMD "with prejudice"; Elan, which manufacturers Cardizem CD for MMD, also must drop its complaint. Hoechst has made a "financial proposal" to Biovail "relating to the withdrawal of the complaint"...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth